Your browser doesn't support javascript.
loading
Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States.
Farber, Harrison W; Germack, Hayley D; Croteau, Nicole S; Simeone, Jason C; Tang, Fei; Paoli, Carly J; Doad, Gurinderpal; Panjabi, Sumeet; De Marco, Teresa.
Afiliação
  • Farber HW; Division of Pulmonary, Critical Care and Sleep Medicine Tufts Medical Center Boston Massachusetts USA.
  • Germack HD; Janssen Scientific Affairs, LLC Titusville New Jersey USA.
  • Croteau NS; Real World Evidence Cytel Waltham Massachusetts USA.
  • Simeone JC; Real World Evidence Cytel Waltham Massachusetts USA.
  • Tang F; Real World Evidence Cytel Waltham Massachusetts USA.
  • Paoli CJ; Janssen Scientific Affairs, LLC Titusville New Jersey USA.
  • Doad G; Actelion Pharmaceuticals Titusville New Jersey USA.
  • Panjabi S; Janssen Scientific Affairs, LLC Titusville New Jersey USA.
  • De Marco T; Division of Cardiology University of California, San Francisco San Francisco California USA.
Pulm Circ ; 14(2): e12326, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38623409
ABSTRACT
Information on factors leading to pulmonary arterial hypertension (PAH) treatment discontinuation is limited. This study analyzed 12,902 new PAH medication users to identify predictors of treatment discontinuation. Treatment by accredited pulmonary hypertension centers and combination therapy with PAH agents from different classes were less likely to result in discontinuation.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article